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Abstract
Background Frameless stereotactic neuronavigation has prov-
en to be a feasible technology to acquire brain biopsies with
good accuracy and little morbidity and mortality. New sys-
tems are constantly introduced into the neurosurgical arma-
mentarium, although few studies have actually evaluated and
compared the diagnostic yield, morbidity, and mortality of
various manufacturer’s frameless neuronavigation systems.
The present study reports our experience with brain biopsy
procedures performed using both the Medtronic Stealth
TreonTM Vertek® and BrainLAB® Varioguide frameless ste-
reotactic brain biopsy systems.
Patients and methods All 247 consecutive biopsies from Jan-
uary 2008 until May 2013were evaluated retrospectively. One
hundred two biopsies each were performed using the
Medtronic (2008–2009) and BrainLAB® system (2011–
2013), respectively. The year 2010 was considered a transition
year, in which 43 biopsies were performed with either system.
Patient demographics, perioperative characteristics, and histo-
logical diagnosis were reviewed, and a comparison was made
between the two brain biopsy systems.
Results The overall diagnostic yield was 94.6 %, i.e., 11 bi-
opsies were nondiagnostic, 5 (4.9 %) with the Medtronic and
6 (5.9%) with the BrainLAB® system. No differences besides
the operating time (108 vs 120 min) were found between the
two biopsy methods. On average, 6.6 tissue samples were
taken with either technique. Peri- and postoperative complica-
tions were seen in 5.3 % and 12.9 %, consisting of three
symptomatic hemorrhages (1.2 %). Biopsy-related mortality
occurred in 0.8 % of all biopsies.
Conclusions Regarding diagnostic yield, complication rate,
and biopsy-related mortality, there seems to be no difference
between the frameless biopsy technique from Medtronic and
BrainLAB®. In contemporary time, the neurosurgeon has
many tools to choose from, all with a relatively fast learning
curve and ever improving feasibility. Thus, the issue of choice
involves not the results, but the familiarity, end-user friendli-
ness, and overall comfort when operating the system.
Keywords Frameless stereotaxy . Biopsy . Varioguide .
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Introduction
The treatment of various intracranial lesions, despite progress
in radiological techniques, largely still depends on the histo-
logical diagnosis. When open surgical biopsy or resection is
not considered appropriate, brain needle biopsy has proven to
be a safe and effective means of acquiring a diagnosis. Diag-
nostic yield has been shown to be between 83.6 and 100 %,
withmorbidity and mortality ranging from 0.7 to 16.1% and 0
to 3.9 %, respectively [4]. Nevertheless, a question remains
about the diagnostic accuracy, ranging 73 to 97 %, which
might be due to sampling error and a lack of standardized
criteria of diagnostic yield [4, 9]. Therefore, many techniques
are currently employed to increase the yield as well as accu-
racy to improve the clinical significance and prognostic value
of brain biopsy methods, such as radiological imaging
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techniques, intraoperative imaging, frozen section analysis,
and even robotics [1, 2, 4, 8, 10–14, 16, 17].
There is no question that frameless stereotactic
neuronavigation has been successfully proven to be a feasible
technology to acquire brain biopsies with good accuracy and
little mortality [4, 8, 11, 16]. Furthermore, its use fans out into
others areas, such as placement of deep brain electrodes for
epilepsy surgery or the treatment of Parkinson’s disease [5, 6].
Manufacturers of neuronavigation devices are rapidly intro-
ducing new frameless stereotaxy systems into the neurosurgi-
cal armamentarium. There are, however, no studies of which
we are aware that have actually evaluated and compared the
diagnostic yield, morbidity, and mortality of various manufac-
turer’s frameless neuronavigation systems in stereotactic
frameless brain needle biopsies.
The present study reports our experience with brain biopsy
procedures performed with both the Medtronic Stealth
TreonTM Vertek® and BrainLAB® Varioguide frameless ste-
reotactic brain biopsy systems.
Patients and methods
No IRB approval is needed for retrospective cohorts in aca-
demic centers in The Netherlands, so no informed consent was
required from any of the patients. Files of all consecutive
patients undergoing frameless image-guided stereotactic brain
biopsy procedures at the Erasmus Medical Centre from Janu-
ary 2008 until and includingMay 2013 were reviewed. A total
of 247 biopsies were performed in 242 patients. All biopsies
performed before January 2010 were performed with the
Medtronic Stealth TreonTM Vertek® frameless stereotactic
brain biopsy system. In this year the BrainLAB® Varioguide
frameless stereotactic brain biopsy system was introduced in
our clinic, which would replace the former. In the Btransition^
period between January and December 2010, all 43 biopsies
were performed using one of the two frame-based techniques
(19 with Medtronic Stealth TreonTM Vertek® and 23 with
Brainlab® Varioguide; for one patient the system was not re-
ported in the operative report). Since January 2011 brain bi-
opsies have been exclusively performed using the
BrainLAB® Varioguide neuronavigation system. After the
transition period, we had the Kolibri® system at our disposal,
but we eventually switched to the Curve® BrainLAB® sys-
tem, running these two in parallel in late 2012 and early 2013.
The biopsy system itself, however, remained unchanged, viz.
the Brainlab® Varioguide was used with both.
Patient and preoperative neuroimaging characteristics
Age, gender, and biopsy-related complications (morbidity)
and death (mortality) as well as operating time, biopsy method
used, number of biopsies, and complications were extracted
from case notes and operative reports. The anatomical site of
the targeted lesion was obtained from preoperative computed
tomography or magnetic resonance imaging scans that were
acquired no more than 24 h preoperatively. The eventual
diagnosis was obtained from the pathological report, pre-
pared or supervised by JMK, from which the diagnostic
yield was determined.
The issue of diagnostic yield is a delicate one, as detailed in
several papers [2–4, 8, 9, 11]. Tumor biopsy is a process
involving two potential sampling error points, the operation
itself, depending on which area of the tumor the samples were
taken from, and the pathological investigation, depending on
what microscopic area of the acquired samples will be inves-
tigated. Therefore, we considered three possible diagnostic
options, a full diagnosis, a partial diagnosis (pathologic tissue
but no WHO classification possible), or no diagnosis at all.
Because in the cases where the diagnosis was only partial a
treatment could be initiated based on other characteristics of
the specific patient (radiological aspect, speed of progres-
sion, oncological history), all biopsies where a treatment
could be initiated and tumor tissue was obtained were con-
sidered diagnostic.
As such, a stereotactic biopsy serves its purpose if a spe-
cific patient can get the best specific treatment given all avail-
able data, and not only if it delivers a perfectly classifiable
result, this sometimes being not possible because of shortcom-
ings in the WHO classification.
The diagnostic yield of the biopsies was independently
reviewed by two authors (RD and VV), and the results were
discussed and validated to a common consensus.
Operative technique
The techniques of frameless image-guided stereotactic
biopsies have been described previously for the Stealth
TreonTM Vertek® system (Medtronic Inc., Minneapolis,
MN, USA) [3] as well as the BrainLAB® Varioguide
system (BrainLAB, Feldkirchen, Germany) [7, 19]. All
biopsies were performed using the frameless stereotaxy
protocol under general anesthesia and head fixation in a
three-point Mayfield clamp. Intraoperative image guid-
ance and the surgical plan were obtained using the
Stealth Treon™ Vertek® system in 102 patients from
January 2008 until December 2009 and with the
BrainLAB® Varioguide system in 102 patients from Jan-
uary 2011 until May 2013, respectively. In the transition
year 2010, 19 and 23 biopsies were performed with the
Stealth TreonTM Vertek® and BraiLAB® Varioguide sys-
tem, respectively. For one patient, the biopsy system had
not been reported in the operative report. As to the sur-
geon’s preference either fiducial markers and/or surface-
merging techniques were used to enable operating room
neuronavigational registration. The surgery was
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performed either by neurosurgeons or neurosurgical
trainees under supervision of neurosurgeons. The
trainees performing the surgery were split into two cat-
egories, junior residents, PGY (postgraduate years) 1–3,
and senior residents, PGY 4–6. Tissue samples approx-
imately 8 mm long and 1 mm thick were thus obtained.
In general, four biopsies were obtained at the preop-
eratively suggested target, as well as two to four more
biopsies at a site proximal to the target on the same
biopsy trajectory. The macroscopic appearance of the
acquired tissue sample was assessed as described previ-
ously and, when appropriate, prompted to intraoperative
freeze sectioning (10/247=4.0 %) [4]. If diagnostic tis-
sue was not obtained, all parameters and measurements
were rechecked to ensure accurate localization, after
which a repeat biopsy was performed via the same or
a new trajectory if needed.
Statistical analysis
Database collection and statistical analysis were per-
formed with SPSS 15.0 for Windows (SPSS Inc., Chi-
cago, IL, USA). For comparison between the two
frameless stereotaxy biopsy systems, continuous data
were compared using one-way analysis of variance
(ANOVA) testing for parametric data. For nonparametric
data the Kruskal-Wallis one-way ANOVA test was used.
These are presented as mean values±standard devia-
tions. For multiple comparisons the Bonferroni post-
hoc correction was used. Proportions were compared
with chi-square and Fisher’s exact test where appropri-
ate and presented as percentages. P-values<0.05 were
considered statistically significant.
Results
Table 1 summarizes the patient and perioperative characteris-
tics with respect to the frameless stereotactic biopsy system
used, i.e., Medtronic TreonTM Vertek® vs. BrainLAB®
Varioguide vs. the 2010 transition period. A higher proportion
of males and a higher mean age was observed in the
BrainLAB® group compared to the Medtronic TreonTM
group. The number of biopsies taken and perioperative com-
plications were equal with both biopsy systems. Remarkably,
the total operating time, including anesthetic preparation, was
significantly longer using the BrainLAB® Varioguide.
The distribution of the different tumor sites related to the
biopsy system used is shown in Table 2. There were no sta-
tistically relevant differences between the system used for
frameless brain biopsy and the various tumor locations.
Length of operating time
Over the years that the BrainLAB® system was used (2010–
2013) there was a gradual but nonsignificant decrease in op-
erating time from a median of 130 min to 115min in 2010 and
2013, respectively. Nevertheless, total operating time
remained significantly longer for the BrainLAB® system.
Correction for age, tumor site, or surgeon experience level
(i.e., PGY 1–3, PGY 4–6, or neurosurgeon) did not change
this finding. Therefore, it seems that a biopsy procedure with
the BrainLAB® Varioguide on average takes some 10 min
longer than a biopsy with the Medtronic TreonTM Vertek®.
Table 1 Patient and perioperative characteristics related to biopsy
method
Stealth
TreonTM
(n=102)
Transition
period
(n=43)
BrainLAB®
(n=102)
Male (%) 49.0* 62.8 65.7
Age (years±SD) 54.0±19.7* 56.3±20.0 60.1±15.3
Operating time (min±SD) 108±36* 121±26 120±28
Number of biopsies±SD 7.0±2.9 6.6±2.9 6.4±2.8
Complication (%) 4.9 4.7 5.9
Hemorrhage 2.9 2.3 4.9
Technical failure 2.0 2.3 1.0
Shown are percentages and mean values±standard deviations
(SD). *p<0.05
Table 2 Preoperative anatomical localization of the intended lesion
chosen for biopsy
Stealth
TreonTM
(n=102)
Transition
period
(n=43)
BrainLAB®
(n=102)
Frontal 23 10 21
Temporal 11 5 16
Parietal 21 3 11
Occipital 5 1 4
Frontotemporal* 2 1 3
Frontoparietal 5 3 7
Parietooccipital 7 0 9
Parietotemporal 7 3 4
Temporooccipital 0 0 2
Thalamus/basal ganglia* 16 12 18
Pons/medulla oblongata
cerebellopontine angle
1 3 2
Cerebellum 0 0 2
Supra-/intrasellar** 3 2 2
Third ventricle 0 0 1
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Complications and mortality
Postoperative complications were encountered in 32 proce-
dures (12.9 %), summarized in Table 3. Of these, three symp-
tomatic hemorrhages (1.2 %) were diagnosed via postopera-
tive computed tomography scanning. Furthermore, symptom-
atic postoperative edema was present in 6 (2.4 %) patients and
early focal neurologic deterioration after biopsy was seen in
15 (6.1 %), of which 9 were observed in the BrainLAB®
Varioguide group (8.8 %, p>0.05, compared to the Medtronic
TreonTM group). The incidence of postoperative symptomatic
hemorrhage between the two techniques was equal.
Biopsy-related death was defined as death occurring
within 30 days as a result of symptomatic postoperative
hemorrhage or edema formation and was observed in two
patients, i.e., 0.8 %. There were no differences between
the two biopsy systems.
Diagnostic yield
The overall diagnostic yield was 94.6 %, i.e., a histological
diagnosis was made in 193 of 204 patients or in 11 cases
(5.4 %) the biopsy was nondiagnostic. This was not statisti-
cally different between the Medtronic TreonTM (4.9 %) and
BrainLAB® (5.9 %) stereotactic biopsy techniques. When in-
cluding the transition period patients, the overall diagnostic
yield was 93.5 % (231/247). A nondiagnostic biopsy was
observed in 11.6 % in the transition period (p>0.05). The
lesion locations of nondiagnostic biopsies were frontal (n=
2), frontotemporal (n=1), parietooccipital (n=2), and in the
third ventricle (n=1) for BrainLAB®; parietal (n=2), occipital
(n=1), parietooccipital (n=1), and temporal (n=1) for
Medtronic TreonTM; frontoparietal (n=1), temporal (n=3),
and thalamus (n=1) for the transition period.
When a nondiagnostic biopsy was encountered, follow-up
surgery (either stereotactic or open biopsy or tumor decom-
pression) was recommended to nine patients, of whom two
underwent three more stereotactic biopsies before a diagnosis
could be made (lymphoma, n=3; glioblastoma, n=3; metas-
tasis, n=2; ependymoma, n=1). These nondiagnostic biop-
sies were included in the analysis. Of the remaining four
patients, two were successfully treated for radionecrosis
and one for intracerebral abscess; the fourth was conclud-
ed to have an infarction after meticulous analysis for a
demyelinating disease.
On average, 6.6 (range: 1 – 20) tissue samples were taken
during each procedure with either frameless stereotaxy tech-
nique (Table 1). Table 4 shows the histological diagnoses that
were made on the tissue samples taken by either system. In ten
cases, seven in Medtronic TreonTM (6.9 %) and three in
BrainLAB® (2.9 %; p<0.05), an intraoperative frozen-
section diagnosis was requested. All of these included diag-
nostic biopsies.
Discussion
The main purpose of stereotactical biopsy systems, frameless
or otherwise, is to produce a safe, fast, reliable and easy diag-
nostic biopsy. For this purpose, many different systems are
available to the neurosurgeon, each with its distinctive set of
qualities. We present a retrospective comparison between the
Medtronic TreonTM Vertek® and the BrainLAB® Varioguide
systems. Our diagnosis yield overall was 94.6 %. Morbidity
andmortality profiles were also comparable with reports in the
literature [1, 2, 7–10, 12, 16].
There was no difference in diagnostic yield between
the two systems, which we defined as the likelihood of
a biopsy producing pathological tissue to be analyzed,
regardless of whether it could be included in the World
Health Organization WHO/Central Nervous System CNS
Table 3 Postoperative complications
(%) Stealth
TreonTM
(n=102)
Transition
period
(n=43)
BrainLAB® (n=102)
None 91.2 83.7 84.3
Hemorrhage 1.0 0 2.0
Edema formation 3.9 2.3 1.0
Focal neurology 2.9 7.0 8.8
Others* 1.0 4.7 3.9
Biopsy-related death 0 0 2.0
Data are presented as percentages. There are no differences between the
biopsy procedures. * Others include psychosis, hyperglycemia, epilepsy,
hypertension, and diabetes insipidus
Table 4 Histological diagnoses made on tissue samples acquired by
stereotactic biopsy
Stealth TreonTM
(n=102)
Transition
period (n=43)
BrainLAB®
(n=102)
Nondiagnostic 5 5 6
Malignant glioma 59 21 42
Low-grade glioma 9 5 15
Lymphoma 11 9 20
Metastasis 2 1 7
Infection/vasculitis/MS/
abscess
12 1 9
Craniopharyngioma
cysts*
2 1 1
Medulloblastoma 0 0 2
Others 2 0 0
MS=multiple sclerosis; others include malignant peripheral nerve sheath
tumor and hematoma
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classifications [9], as there are still pathological entities
that cannot be classified according to this system.
A descending trend can be noticed in the number of
times the team asked for a frozen section histology ex-
amination to be performed during the operation, possibly
reflecting the increase in experience and confidence
using the frameless stereotactic systems. However, the
operating time was significantly longer using the
BrainLAB® Varioguide, in part probably pointing to-
ward the learning curve, not pertaining to the act of
biopsying, but to the system itself, as shown by a grad-
ual decrease of 12.5 % in median operating time over
the years. Nevertheless, in our cohort the total operating
time remained approximately 11 %, or 10 min, longer
when using the BrainLAB® system, even after correc-
tion for some well-established confounders.
Patients undergoing biopsy with the BrainLAB®
Varioguide show significantly more frequent focal neurologi-
cal signs postoperatively, but this was not correlated with in-
creased hemorrhage or perilesional edema. Only speculations
are possible as to why this has occurred, statistical evidence
not pointing to any reason in particular. Some reports [18]
suggest that the size of the needle correlates with the risk of
hemorrhage, but this could not be established in our series
(outer needle diameter 2.2 and 1.8 mm and cutting window
length 7 and 10 mm for the Stealth TreonTM Vertek® and
Brainlab® Varioguide, respectively).
Two deaths occurred, one concerning an 81-year-old male
with a parieto-occipital glioblastoma who suffered a basilar
artery thrombosis 8 days after the operation. The second con-
cerned a 53-year-old male with a multiloculated mixed ana-
plastic oligo-astrocytoma expanding the better part of the right
cerebral hemisphere who suffered a large, deep intracerebral
hematoma and subsequently expired 9 days after the opera-
tion. These cases are thus not attributable to the stereotactic
systems themselves.
Using both systems we were able to reach a diagnostic
yield that was higher even than those usually reported in the
literature [2, 7, 9, 10, 15]. Counterintuitively, the intraopera-
tiveMRI-enhanced biopsies, which actively provide feedback
as to the changes the lesion to be biopsied is undergoing,
yielded the worst diagnostic yield [9].
We can thus conclude that both systems are effective,
safe, and reliable tools, which when used properly have
an excellent diagnostic yield, above 95 %. Despite minor
differences, these tools are both part of a well-crafted
diagnostic armamentarium available to contemporary neu-
rosurgeons, which should be put to work in order to yield
quick and precise diagnostic results. Future prospective
studies are needed to compare the effectiveness of these
and other available products, including parameters such as
end-user satisfaction, subjective intraoperative stress, and
overall comfort, among others.
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Comments
Intracranial biopsies are an important part of the workload in neurosur-
gery. In the retrospective study, Verploegh et al. compare their experience
with two of the so-called frameless stereotactic systems. The term
Bframeless^ is a misnomer as both systems require the patient to be
fixated with pins in a frame; they are just not classical stereotactic frames.
The benefit of the frameless systems is that there is no need for an addi-
tional scan once the patient has been fixated in the frame. This allows for
an improved workflow and convenience for the patient. The drawback is
a slight reduction in accuracy compared to the classical frame-based sys-
tems. We have recently published that high workflow efficiency and
patient comfort can be obtained with the classical frame-based stereotac-
tic system in combination with intraoperative CT [1].
The important finding by Verploegh et al. is the similar diagnostic
yield and safety with their current system (Brainlab Varioguide) com-
pared to their previous system (Medtronic Stealth Treon Vertek). The
procedure time was approximately 11 % longer with the Brainlab system,
with median procedure times around 2 h. All procedures used general
anesthesia.
It is our routine in Copenhagen to perform stereotactic biopsies under
local anesthesia in adults. With our concept we have median procedure
times (patient arrives-patients leaves OR) of 76 min for awake patients
and 89 min for intubated pediatric patients [1].
Jannick Brennum
Copenhagen, Denmark
1. Skjøth-Rasmussen J, Jespersen B, Brennum J (2015). The use of
Brainlab iCT for frame-based stereotactic procedures. Acta Neurochir
157(8) 1437–1440.
In this well-written article the authors retrospectively analyzed their
experience using two different navigation systems for frameless intracra-
nial biopsy, each on 102 patients. The use of neuronavigation to perform
stereotactical frameless biopsies has been disseminated worldwide in the
last decades, and different strategies have been developed by diverse
companies. Overall, the results are excellent with good accuracy and little
mortality. This study has the great value of comparing two systems to
match up to the diagnostic yield, morbidity, and mortality.
The results show no differences between the two systems besides the
different operating time. The issue is of neurosurgical impact and very
interesting for daily practice. The results should be confirmed in prospec-
tive studies, including other commercially available products (i.e.,
Stryker, Fiagon, Micromar, Medtech, etc.) and taking into consideration
other parameters such as the subjective end-user satisfaction, comfort,
and subjective stress during the procedures.
Alex Alfieri, Francesco Ferri,
Neuruppin, Germany
2016 Acta Neurochir (2015) 157:2011–2016
